AstraZeneca PLC (AZN) Stock Analysis
Verdict: HOLD
Oncology growth (+26%) and M&A speculation create a value floor, but technical breakdown and M&A arbitrage volatility require a tiered entry.
Investment score: 64/100
Analysis as of
Is AstraZeneca PLC stock worth reviewing? The TradeMates thesis
AstraZeneca is a high-margin oncology powerhouse currently trading at a technical discount due to M&A rumors. Fundamental growth remains intact.
7-factor investment score
- Valuation: 68/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 40/100 (weight 15%)
- Earnings Quality: 55/100 (weight 15%)
- Insider Sentiment: 45/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 60/100 (weight 15%)
AstraZeneca PLC opportunities and risks
What speaks for AZN
- Oncology Dominance
What speaks against AZN
- M&A Execution and Antitrust Risk
Peers and competitors
- AZN.L
- GSK.L
- HLN.L
- HIK.L
- AGY.L
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AZN | 23.4x | 4.0x | 13.3x | 79.3% | 17.0% | 3.5% |
| AZN.L | 23.4x | 4.0x | 13.3x | 79.3% | 17.0% | 3.5% |
| GSK.L | 15.9x | 2.3x | 8.4x | 73.3% | 14.5% | 7.5% |
| HLN.L | 19.3x | 2.9x | 13.9x | 64.8% | 15.1% | 3.7% |
| HIK.L | 0.2x | 1.3x | 8.6x | 41.4% | 12.0% | 4.3% |
| AGY.L | n/a | 4.6x | n/a | 41.2% | -85.5% | -14.1% |
| Peer median | 15.9x | 2.9x | 8.6x | 64.8% | 14.5% | 3.7% |
Frequently asked questions about AstraZeneca PLC (AZN)
Is AZN stock a good investment?
The TradeMates model rates AstraZeneca PLC as HOLD with an investment score of 64/100. AstraZeneca is a high-margin oncology powerhouse currently trading at a technical discount due to M&A rumors. Fundamental growth remains intact. This is algorithmic model output, not personal investment advice.
Is AZN stock a buy?
The TradeMates model verdict for AZN is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.